Back

PCSK9 Inhibitors - State of the art

28 August 2018 (08:30 - 08:48)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors - For the many or the few? Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Jane Armitage

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting
Doctor U. Kassner (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial
Professor P. Sever (London, GB)
Abstract Slides Video
Presentation thumbnail
Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation
Doctor T. Priyadechawarawong (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
Future hurdles in PCSK9 - Inhibition.
Professor E. Stein (Cincinnati, US)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors - For the many or the few?

The Event

Event poster

ESC Congress 2018

28 August 2018 08:30 CET
You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
ESC TV Today
Episode 7: Coronary spasm - Sex differences in heart failure
thumbnail
Congress Session
Optimal management of chronic coronary syndromes: putting the evidence into practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources